Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies
Shujie J. Wang(Pfizer (United States)), Mohammed Jemal(Haramaya University), Aberra Fura(Bristol-Myers Squibb (United States)), David Wang‐Iverson(Stockton University), Russell Weiner(Mochida Pharmaceutical (Japan)), Adrienne A. Tymiak(Bristol-Myers Squibb (United States)), Paul E. Morin(Bristol-Myers Squibb (United States)), Murli Krishna, Guodong Chen(Bristol-Myers Squibb (United States)), Karen Price(Purchase College), Timothy Olah(Bristol-Myers Squibb (United States)), Steven T. Wu(Bristol-Myers Squibb (United States)), Jochem Gokemeijer(Bristol-Myers Squibb (Germany))
Cited by 63
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project
|Toxicology and Applied Pharmacology|2003|386
Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis
|Gastroenterology|2015|328
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183